Amazonas Florestal bets on CBD and light-cannabis for the future of medicine
The United Kingdom is the first country to start trials to assess whether drugs based on CBD could possibly extend life for thousands of patients with aggressive brain tumours. Coordinated by the University of Birmingham, the study takes in account the fact that cannabinoids have well-described effects in the brain and, by consequence, the substance could hold potential to tackle different cancers.
This is just one additional step to the promising future that CBD is paving for public health, since the compound is already being researched in the case of other conditions like epilepsy, Parkinson’s disease, chronic pain, inflammation, anxiety, and even insomnia. Multiple studies have shown that CBD has anti-inflammatory effects and is often seen as a natural solution to relieve pain, reduce anxiety and depression, as well to combat stress levels and improve sleep. This is what is stated by Jose Giron, COO of Amazonas Florestal Ltd, a diversified timber company focused on sustainable forestry practices, leader in the production of highest quality.
Even though cannabinoids are often associated with Marijuana, Giron explains that CBD is one of the many compounds found in the cannabis plant. In the case of Marijuana, it is the psychoactive component tetrahydrocannabinol (THC) that is used in its formulation. “Essentially, our body is naturally programmed from birth to interact with these compounds. CBD is the compound associated with benefits such as reduced anxiety, pain relief, and treating epilepsy, whereas THC produces the ‘high’ feeling,” explains the COO.
With such prominent benefits, cannabinoids have indeed grown popular for the past years, especially in the case of “light cannabis.” During the pandemic, U.S. cannabis sales increased by 67% in 2020, but such intensification did not overcome public interest in Marijuana, where legalised. Such information stresses the fact that CBD or light cannabis cannot substitute the effects of the psychoactive drug, but rather be used for medicinal ends only. “Scientists have already discovered CBD to have benefits when treating rather difficult diseases such as Alzheimer’s, Crohn’s, Parkinson’s, glaucoma, chronic pain, and loss of appetite,” explains Giron, who is confident that at the current pace, the taboo surrounding the cannabis plant has its days counted.
As a matter of fact, Giron believes that as CBD becomes legalised in Europe and in other continents, not only consumers will benefit from this more natural product and its effects, but also businesses may take advantage of this increasingly promising market. In 2020, the global CBD market size was already valued at USD 3 billion, but the rates are expected to grow at a compound annual growth rate (CAGR) of 21% for the next eight years. “Needless to say, Governments could highly benefit from the legalisation of CBD in their jurisdiction, with sales going through the roof,” adds the COO of Amazonas Florestal.
The company has thus taken advantage in the CBD race for already having developed a strong business relationship with Precision Extraction Solutions, a widely recognised cannabis extraction equipment manufacturer in the United States. “At Amazonas Florestal, we strongly believe in the positive impact that CBD can have on people’s lives,” says Jose Giron. “We are determined to produce a THC-Free Oil that provides the benefits of cannabis to all our clients, without the psychotropic effect that eludes many from even trying this revolutionary, natural health treatment.”
Based in Miami, in the United States, the company also has strong connections with Latin American countries. By observing the development of legalisation in Europe, Giron argues that before the end of the decade, the CBD market could well be worth USD 60 billion, a rate that is 20x what it is worth today. Coupled with the product’s natural healing properties and its high demand in the world market, CBD is only prone to,